Apyx Medical (NASDAQ:APYX) Price Target Raised to $6.00 at Craig Hallum

Apyx Medical (NASDAQ:APYX) had its price target lifted by Craig Hallum from $5.00 to $6.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

APYX has been the topic of several other reports. Zacks Research upgraded Apyx Medical to a “hold” rating in a research note on Wednesday, December 17th. Roth Mkm assumed coverage on shares of Apyx Medical in a report on Monday, December 15th. They issued a “buy” rating and a $6.00 price target for the company. Citizens Jmp upgraded shares of Apyx Medical from a “market perform” rating to an “outperform” rating and set a $8.00 price objective on the stock in a research note on Wednesday, November 12th. BTIG Research upgraded Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a research note on Wednesday. Finally, Wall Street Zen raised Apyx Medical to a “hold” rating in a research report on Saturday, November 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $6.50.

Apyx Medical Price Performance

Shares of APYX stock opened at $3.93 on Wednesday. The firm has a market cap of $150.29 million, a P/E ratio of -14.56 and a beta of 1.61. The company has a debt-to-equity ratio of 5.69, a current ratio of 4.44 and a quick ratio of 3.61. Apyx Medical has a 1-year low of $0.76 and a 1-year high of $4.50. The firm has a fifty day moving average of $3.75 and a two-hundred day moving average of $3.31.

Apyx Medical (NASDAQ:APYX) last issued its earnings results on Tuesday, March 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03. The business had revenue of $19.16 million for the quarter, compared to analyst estimates of $19.12 million. Apyx Medical had a negative net margin of 21.22% and a negative return on equity of 139.09%. As a group, research analysts anticipate that Apyx Medical will post -0.68 earnings per share for the current fiscal year.

Institutional Trading of Apyx Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Kingsview Wealth Management LLC boosted its stake in Apyx Medical by 9.4% during the 2nd quarter. Kingsview Wealth Management LLC now owns 191,597 shares of the company’s stock valued at $431,000 after purchasing an additional 16,502 shares in the last quarter. Perkins Capital Management Inc. increased its holdings in shares of Apyx Medical by 4.9% in the fourth quarter. Perkins Capital Management Inc. now owns 85,000 shares of the company’s stock valued at $298,000 after buying an additional 4,000 shares in the last quarter. AIGH Capital Management LLC bought a new position in shares of Apyx Medical in the fourth quarter valued at $3,867,000. Huntleigh Advisors Inc. acquired a new stake in shares of Apyx Medical during the 4th quarter valued at $827,000. Finally, Silverberg Bernstein Capital Management LLC boosted its stake in shares of Apyx Medical by 4.7% during the 4th quarter. Silverberg Bernstein Capital Management LLC now owns 1,033,003 shares of the company’s stock worth $3,616,000 after acquiring an additional 46,500 shares in the last quarter. 55.33% of the stock is currently owned by institutional investors.

Key Stories Impacting Apyx Medical

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: Craig Hallum raised its price target to $6.00 and initiated/maintained a “buy” view, implying ~52.7% upside from recent levels — a catalyst for bullish investor sentiment. Article Title Article Title
• Positive Sentiment: BTIG upgraded APYX from Neutral to Buy and set a $6.00 target, reinforcing the positive analyst momentum. Article Title Article Title
• Positive Sentiment: Q4 results slightly beat expectations: EPS of ($0.03) vs. consensus ($0.06) and revenue of $19.16M vs. $19.12M — the beat and management commentary (record revenue / strategic growth) support the upgrade momentum. Article Title Press Release
• Positive Sentiment: Management raised FY2026 revenue guidance to $57.5M–$58.5M vs. street ~$55.9M and outlined a 9%–11% revenue growth target as AYON rollout accelerates — suggests better topline visibility into 2026. Press Release Article Title
• Neutral Sentiment: Analyst coverage and press summaries (earnings breakdowns and call highlights) are amplifying the story for investors but mostly restate the beats/guidance. Article Title
• Negative Sentiment: Short interest has shown increases earlier in the period (Feb short interest ~173,573 shares, +22.3%), and the company still posts negative margins and ROE — these remain downside risks if execution lags. (March short-interest data appears inconsistent/zero in some reports and may reflect a reporting anomaly.)

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.